Literature DB >> 20354615

Bis(thiosemicarbazones) as bifunctional chelators for the room temperature 64-copper labeling of peptides.

Rebekka Hueting1, Martin Christlieb, Jonathan R Dilworth, Elisa García Garayoa, Véronique Gouverneur, Michael W Jones, Veronique Maes, Roger Schibli, Xin Sun, Dirk A Tourwé.   

Abstract

A range of new carboxylate functionalised bis(thiosemicarbazone) ligands and their Cu(II) complexes have been prepared, fully characterised and radiolabeled in high yield with both (64)Cu and (99m)Tc. Conjugation to a bombesin derivative was achieved using standard solid phase synthetic methodologies and the (64)Cu-labeled conjugate was shown to have good tumour uptake in mice with xenografted PC-3 tumours.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20354615     DOI: 10.1039/b925128f

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  4 in total

1.  Development of hypoxia enhanced 111In-labeled Bombesin conjugates: design, synthesis, and in vitro evaluation in PC-3 human prostate cancer.

Authors:  Nilesh K Wagh; Zhengyuan Zhou; Sunny M Ogbomo; Wen Shi; Susan K Brusnahan; Jered C Garrison
Journal:  Bioconjug Chem       Date:  2012-02-16       Impact factor: 4.774

2.  VPAC1 Targeted 64Cu-TP3805 kit preparation and its evaluation.

Authors:  Sushil K Tripathi; Pardeep Kumar; Edouard J Trabulsi; Sung Kim; Peter A McCue; Charles Intenzo; Adam Berger; Leonard Gomella; Mathew L Thakur
Journal:  Nucl Med Biol       Date:  2017-05-03       Impact factor: 2.408

Review 3.  Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers.

Authors:  David G Calatayud; Sotia Neophytou; Eleni Nicodemou; S Giuseppe Giuffrida; Haobo Ge; Sofia I Pascu
Journal:  Front Chem       Date:  2022-04-12       Impact factor: 5.545

Review 4.  Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals.

Authors:  Zhengxin Cai; Carolyn J Anderson
Journal:  J Labelled Comp Radiopharm       Date:  2013-12-18       Impact factor: 1.921

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.